MedTrace Logo

Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered

NCT05332340 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-03-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate pharmacokinetics, safety and tolerability profile of BZ371A topically administered in healthy patients.

Conditions

Interventions

DRUG

BZ371A

Single dose topical administration of 1.5 mL with a concentration of 5 mg/mL of BZ371A.

Sponsors & Collaborators

  • Azidus Brasil Scientific Research and Development Ltda

    collaborator OTHER

  • Biozeus Biopharmaceutical S.A.

    lead INDUSTRY

Principal Investigators

  • Regina M Doi · Azidus Brasil Pesquisa Científica e LTDA

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-16
Primary Completion
2022-11-30
Completion
2022-11-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05332340 on ClinicalTrials.gov